Researchers Have Discovered the First Effective Treatment for a Rare Blood Vessel Disorder

The trial of pomalidomide for treating hereditary hemorrhagic telangiectasia was halted early due to positive results. A clinical trial has shown that the cancer drug pomalidomide is both safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder affecting over 1 in 5,000 people globally. Led by Keith McCrae, M.D., from the […]

Source link